A study investigated the longitudinal metabolic effects of Tirzepatide and Semaglutide in patients with type 2 diabetes (T2D) following a 28-week clinical trial.
Mechanistic Analysis and Key Findings
The research utilized a mechanistic longitudinal model incorporating fasting glucose, fasting insulin, insulin sensitivity, and beta-cell function to analyze the data. The model allowed for quantification of hepatic glucose production (HGP) and the isolation of drug effects on HGP. The study found that both Tirzepatide 15 mg and Semaglutide 1 mg improved fasting glucose. Tirzepatide demonstrated superior efficacy in this comparison.
Longitudinal Metabolic Changes
The model revealed an initial increase in beta-cell function, followed by a decline in insulin sensitivity, representing a reversal of the typical progression of T2D. The superior fasting glucose control observed with Tirzepatide was primarily attributed to greater insulin-independent suppression of HGP. Patients exhibiting low responses to treatment displayed deficient HGP suppression. Simulations suggested that enhancing HGP suppression could improve fasting glucose without inducing beta-cell stress associated with sustained hypersecretion. Simulated weight loss accelerated early glycemic improvement, but did not further reduce long-term fasting glucose levels. The findings indicate that greater suppression of hepatic glucose production is associated with greater efficacy in improving fasting glucose. Therapeutic strategies focused on suppressing HGP may offer metabolic benefits beyond direct enhancement of beta-cell function or additional weight loss.